Your diagnosis should be as well!

Your Access to personalized diagnostics

Lorem ipsum dolor sit amet, consectetur adipiscing elit.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla suscipit finibus neque, id porttitor velit commodo ornare. Mauris volutpat dignissim […]

Mehr erfahren

GeneSurge is your access to individualized diagnostics

Even though we classify tumors according to their place of origin and appearance, each one remains somewhat different at the molecular level. And that is exactly what makes each cancer an individual disease. This fact ultimately creates a need for individual and detailed information to enable personalized treatment that is specific to the individual patient.


Every cancer is as individual as the patient.


Only for those who get cancer and systemic diseases recognized early treatment can be started promptly and effectively.


Once a tumor grows and spreads, it releases components of itself to the blood.

GeneSurge aims to allow each patient to be treated as best as possible

GeneSurge has a clear goal: to provide sufficient information so that each patient can receive the drugs that work most effectively against the specific tumor. In order to achieve this, several factors are taken into account in the analysis, whereby conclusions can be made that a tumor responds - due to its heterogeneity - partly even with certain areas sensitive to a treatment. If the blood is examined with highly sensitive methods, then the individual tumor components can be made measurable, which leads to an overall picture of the tumor and it is possible without any access to the tissue. This is called a liquid biopsy.

How is the test working?

Each person is individual and therefore all results are compared with the personal genetic background, so that the changes within the tumor can be better determined. For this purpose, the test isolates the DNA and RNA from all samples, which are sequenced (NGS) in the subsequent test procedure.


Individual patient

Our test is characterized by a cycle in which the patient always stands in the center and whose start and end point he is.

[ Show less ]

Blood collection

Blood is drawn with various blood collection tubes that specifically stabilize certain components. This allows a differentiated evaluation.
+ Tumor tissue: Already taken tumor material (FFPE, formalin fixed, paraffin embedded tissue; pathology sample) is used for testing. The extracted blood is used for the adjustment.

[ Show less ]

Shipping to the laboratory

The collected patient samples are sent to the lab.

[ Show less ]

Isolation of RNA and DNA

In order to obtain a correspondingly differentiated result, RNA and DNA are isolated from all samples.

[ Show less ]

Analysis via sequencing

Now it comes to the testing of the samples. All tests are standardized to ensure the highest quality. The analysis is carried out by means of sequencing (Next Generation Sequencing, NGS). In DNA sequencing, all coding gene regions (whole exomes) are tested in detail, generating approximately 50 million individual values for the RNA. This allows a data analysis that specifically addresses the patient.

[ Show less ]

data analysis and finding of relevant information

The data analysis then leads to the fusion of all data (DNA, RNA) with a comparison of the patient groups with known therapy output from the databases. This network analysis provides new facts and creates the unique opportunity to find new ways of therapy. For this purpose, all approved drugs are virtually tested for a possible effect.

[ Show less ]

Filtering of data and creation of a signature for targeted therapy

The specific and therapy-relevant data are summarized. In addition, information about the immune status (tumor and blood) is generated. Individual biomarkers in the blood that enable therapy monitoring are identified and an understanding of the genetic background is developed to estimate possible side effects.

[ Show less ]

Sending of the report

The collected information is sent to the doctor and the patient and this allows the physician to choose the best possible treatment for the individual patient.

[ Show less ]

Individual patient

The patient now has an individual information and data overview in his hands, which makes it possible to start immediately with a tailor-made treatment by the attending physician.

[ Show less ]

Your get tailored therapy recommendation information

The result of the tests includes a listing of possible therapeutics as well as the sensitivity of the tumor. In addition, a targeted therapy monitoring is possible after this first test. For this purpose, individual and tailored to the patient tumor markers are first identified from the data. These can then be checked in almost real time during the course of therapy using other technologies (quantitative polymerase chain reaction, qPCR). In this way, the treatment can be individually adapted months before the results of imaging procedures.

Tailored Therapy by us, with treatment by your physician

The commissioning of a GeneSurge always takes place in the first step via a patient consent. You or your doctor will be sent sample tubes for the blood test. In the case of tumor analysis, the doctor instructs a pathologist, who stores your tumor tissue, to send a certain amount of this sample to our laboratory - this is a very small amount (15 so-called blanks). The analysis time after receipt of the sample in the laboratory is about one month, billing takes place immediately after receiving the sample. Please remember that it is important that you have discussed everything with your attending physician to ensure the best possible use of each patient's tests. The results are communicated to both the doctor and you as a patient.

The tests will provide you with valuable information regarding a possible response of a tumor to different drugs. Nevertheless – understandably – the therapy is in the hands of the attending physician. For this reason, it is particularly important to communicate the data obtained from the test as early as possible.

In order for the results to be transmitted smoothly and promptly, please notify your treating physician with the patient’s consent. The findings sent to him will specifically mention therapeutics that your doctor considers appropriate. In addition, the findings will be sent directly to him. You have further questions about the process in this regard?

Then please contact GeneSurge’s info mail.


Robert Loewe has been working in the field of diagnostics since 2000, with parts of his development findings currently use in blood and tissue analysis. The greatest ambition of his work revolves around the early detection of diseases such as cancer, the personalized diagnostics and tailor-made forms of therapy and thus the chance of each individual patient to improve.



Publikationen (und ich hab bestimmt was vergessen, ich publiziere eigentlich nicht; 2011 war nen Buchkapitel und kompletter Überblick zu einer Unterart von Bioinformatik und 2013 ist die erste Veröffentlichung die NGS und qPCR für Krebsdiagnostik zur Idee der Therapieanpassung verwendet hat):

Kretschmer A., Milo P.-S. , Löwe R., Stief C. G. , Tilki D. Die Genexpressionsanalyse von AMACR in Vollblut als potenzieller diagnostischer Marker des Prostatakarzinoms. 40. Gemeinsame Tagung der Bayerischen Urologenvereinigung und der Österreichischen Gesellschaft für Urologie und Andrologie 15.–17. Mai 2014

Loewe RP. Combinational usage of next generation sequencing and qPCR for the analysis of tumor samples. Methods. 2013; 59:126-131.

Paulis Y, Dinnes D, Soetekouw P, Nelson PJ, Burdach S., Loewe RP, Tjan-Heijnen V, von Luettichau I., Griffioen AW. Imatinib reduces the vasculogenic potential of plastic tumor cells; Current Angiogenesis. 2012; 1: 64-71.

von Toerne C, Bedke J, Safi S, Porubsky S, Gretz N, Loewe R, Nelson PJ, Gröne HJ. Modulation of Wnt and Hedgehog signaling pathways is linked to retinoic acid-induced amelioration of chronic allograft dysfunction. Am J Transplant. 2012 Jan;12(1):55-68. 

Loewe RP, Nelson PJ. Microarray bioinformatics. Methods Mol Biol. 2011;671:295-320.

Dehmel S, Wang S, Schmidt C, Kiss E, Loewe RP, Chilla S, Schlöndorff D, Gröne HJ, Luckow B. Chemokine receptor Ccr5 deficiency induces alternative macrophage activation and improves long-term renal allograft outcome. Eur J Immunol. 2010 Jan;40(1):267-78.

Luckow B, Hänggli A, Maier H, Chilla S, Loewe RP, Dehmel S, Schlöndorff D, Loetscher P, Zerwes HG, Müller M. Microinjection of Cre recombinase protein into zygotes enables specific deletion of two eukaryotic selection cassettes and enhances the expression of a DsRed2 reporter gene in Ccr2/Ccr5 double-deficient mice. Genesis. 2009 Aug;47(8):545-58.

Zerwes HG, Li J, Kovarik J, Streiff M, Hofmann M, Roth L, Luyten M, Pally C, Loewe RP, Wieczorek G, Bänteli R, Thoma G, Luckow B. The chemokine receptor Cxcr3 is not essential for acute cardiac allograft rejection in mice and rats. Am J Transplant. 2008 Aug;8(8):1604-13. 

Harzmann R, Esser N, Loewe R, Roberts J, Leenders F, Seifert W, Unger C, Drevs J. Glutaminase (PEG-PGA) increases antitumoral efficacy of cytotoxic agents J Clin Oncol. 2004; 22:3183

Loewe R. Talk and Poster (together with HR Tinneberg) at the 6th Nottingham International Breast Cancer Conference Sep. 2001, Nottingham: ChemoSelect, a chemosensitivity test to predict the response of tumor cells to certain cytostatic agents.


Robert Loewe has been working in the field diagnostics since 2000 and has had the opportunity to participate in a variety of projects. His first work in this regard was the analysis of tumors at the cellular level for chemosensitivity testing at CellControl. After intermediate steps in the field of protein analysis and enzyme research in cancer, Robert Loewe worked for Roche Pharma and Roche Diagnostics in the field of oncology.

Among other things, he has worked on cancer screening as well as therapy prediction of own products for Roche. He was also involved in various projects at other pharmaceutical and diagnostics companies, such as Novartis and other major corporations. Some of his developments are now used in blood and tissue analysis as well as therapy classification of patients. The ultimate goal of Robert Loewe is to make the most up-to-date research and the latest methods available to patients in order to give each one their best possible treatment by the doctor.

His ambition is to personalize the diagnostics so that each treatment can be tailored to the success of the therapy. Robert Loewe´s concern is the early detection of diseases like cancer and in this way the improvement of the prognosis of each individual patient.